1. Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013; 227:311–315.
Article
2. Taïeb A, Picardo M;. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007; 20:27–35.
Article
3. Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol. 2008; 74:701.
Article
4. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012; 51:1206–1212.
Article
5. Park SY, Youn JI, Lim SD. A clinical study of 217 cases of vitiligo. Korean J Dermatol. 1981; 19:145–152.
6. Taïeb A, Picardo M. Epidemiology, definitions and classification. In : Picardo M, Taïeb A, editors. Vitiligo. Berlin: Springer;2010. p. 13–24.
7. Song YJ. The South Korean Health Care System. JMAJ. 2009; 52:206–209.
8. Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013; 24:707–711.
Article
9. Park SJ, Choi NK, Park KH, Woo SJ. Five year nationwide incidence of rhegmatogenous retinal detachment requiring surgery in Korea. PLoS One. 2013; 8:e80174.
Article
10. Lee YK, Jang S, Jang S, Lee HJ, Park C, Ha YC, et al. Mortality after vertebral fracture in Korea: analysis of the National Claim Registry. Osteoporos Int. 2012; 23:1859–1865.
11. Korean Statistical Information Service. Summary of Census Population. accessed on 2013 December 23. Available at:
http://www.kosis.kr.
12. Furue M, Yamazaki S, Jimbow K, Tsuchida T, Amagai M, Tanaka T, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol. 2011; 38:310–320.
Article
13. Lu T, Gao T, Wang A, Jin Y, Li Q, Li C. Vitiligo prevalence study in Shaanxi Province, China. Int J Dermatol. 2007; 46:47–51.
Article
14. Zhao B. Clinical Dermatology. 3rd ed. Nanjing: Jiangsu Scientific Press;2001.
15. Xu YY, Ye DQ, Tong ZC, Hao JH, Jin J, Shen SF, et al. An epidemiological survey for four skin diseases in Anhui. Chin J Dermatol. 2002; 35:406–407.
16. Hann SK, Nordlund JJ. A Monograph on the Basic and Clinical Science. Oxford: Blackwell Science Ltd.;2000.
17. Yu HJ, Park KC, Ahn JS, Lim JG, Kwon TE, Koh WS, et al. Clinical study of vitiligo. Korean J Dermatol. 1998; 36:1037–1042.
18. Narita T, Oiso N, Fukai K, Kabashima K, Kawada A, Suzuki T. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int. 2011; 60:505–508.
Article
19. Silverberg JI, Silverberg NB. Association between vitiligo and atopic disorders: a pilot study. JAMA Dermatol. 2013; 149:983–986.
Article
20. Sawchuk M, Spano F, Loo WJ, Guenther L. The coexistence of psoriasis and vitiligo: a review. J Cutan Med Surg. 2012; 16:300–305.
Article
21. Youn JI. Psoriasis in Korean. Korean J Dermatol. 2012; 50:387–402.
22. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011; 63:40–46.
Article
23. Zhu KJ, Lv YM, Yin XY, Wang ZX, Sun LD, He SM, et al. Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PLoS One. 2011; 6:e23089.
Article
24. Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011; 36:292–297.
Article
25. Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009; 60:256–260.
Article
26. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007; 356:1216–1225.
Article
27. Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid. 2010; 20:745–754.
Article